secwatch.observer — SEC 8-K summary
======================================

Issuer:     MIRA PHARMACEUTICALS, INC. (MIRA)
CIK:        0001904286
Form:       8-K
Filed at:   2025-07-10T23:59:59+00:00
Accession:  0001641172-25-018595
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

MIRA reports SKNY-1 reverses anxiety behavior in animal model, differentiating from older CB1 drugs
--------------------------------------------------------------------------------

- SKNY-1 reversed anxiety-like behavior in zebrafish induced by a CB1 activator, normalizing to control or better levels.
- Prior results showed SKNY-1 achieved up to 30% weight loss, reversed nicotine craving, and preserved muscle mass in animal models.
- SKNY-1 is designed to avoid CNS side effects that halted earlier CB1 drugs like rimonabant.
- Company is preparing for shareholder approval for acquisition of SKNY Pharmaceuticals; expects to start IND-enabling studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225018595/0001641172-25-018595-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1904286/000164117225018595/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-018595

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer